Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 238

1.

Long-term risk for kidney donors with hypertension at donation - a retrospective cohort study.

Haugen AJ, Langberg NE, Dahle DO, Pihlstrøm H, Birkeland KI, Reisaeter A, Midtvedt K, Hartmann A, Holdaas H, Mjøen G.

Transpl Int. 2019 Apr 15. doi: 10.1111/tri.13443. [Epub ahead of print]

PMID:
30983060
2.

A Fully Automated Method for the Determination of Serum Belatacept and Its Application in a Pharmacokinetic Investigation in Renal Transplant Recipients.

Klaasen RA, Egeland EJ, Chan J, Midtvedt K, Svensson M, Bolstad N, Fellström B, Holdaas H, Åsberg A, Bergan S, Vethe NT, Warren DJ.

Ther Drug Monit. 2019 Feb;41(1):11-18. doi: 10.1097/FTD.0000000000000580.

PMID:
30633722
3.

Regarding age-calibrated glomerular filtration rate.

Mjoen G, Reisæter A, Hartmann A, Dahle DO, Holdaas H.

Kidney Int. 2019 Jan;95(1):234-235. doi: 10.1016/j.kint.2018.10.003. No abstract available.

PMID:
30606421
4.

Genetic markers associated with long-term cardiovascular outcome in kidney transplant recipients.

Pihlstrøm HK, Mjøen G, Mucha S, Franke A, Jardine A, Fellström B, Dahle DO, Holdaas H, Melum E.

Am J Transplant. 2019 May;19(5):1444-1451. doi: 10.1111/ajt.15191. Epub 2018 Dec 18.

PMID:
30457209
5.

Long-term renal allograft survival: a quiet revolution.

Jardine AG, Hartmann A, Holdaas H.

Kidney Int. 2018 Nov;94(5):853-855. doi: 10.1016/j.kint.2018.08.005.

PMID:
30348301
6.

Establishing a Core Outcome Measure for Life Participation: A Standardized Outcomes in Nephrology-kidney Transplantation Consensus Workshop Report.

Ju A, Josephson MA, Butt Z, Jowsey-Gregoire S, Tan J, Taylor Q, Fowler K, Dobbels F, Caskey F, Jha V, Locke J, Knoll G, Ahn C, Hanson CS, Sautenet B, Manera K, Craig JC, Howell M, Rutherford C, Tong A, Harden P, Hawley C, Holdaas H, Israni A, Jesse M, Kane B, Kanellis J, Kiberd B, Kim J, Larsen C, Leichtman A, Lentine K, Malone A, Mannon R, Oberbauer R, Patzer R, Peipert JD, Phan HA, Poggio E, Reed R, Scandling J, Tang I, Watson C, Contrares D, Contreras P, Cross D, Juodvalkis E, Koide D, Koide J, Kozarewicz A, Kozarewicz L, Kozarewicz R, Koritala A, Lisiecki E, Lipuma C, Lyman M, Mueller R, Mueller G, Noble L, Nolan N, Nolan S, Thomas J, Urbancyzk L, Zerante J, Zerante S; SONG-Tx Life Participation Workshop Investigators; Health professionals (*includes 2 patients from the SONG-Tx Graft Health Expert Working Group); Patients and family members.

Transplantation. 2019 Jun;103(6):1199-1205. doi: 10.1097/TP.0000000000002476.

PMID:
30300284
7.

High tacrolimus clearance - a risk factor for development of interstitial fibrosis and tubular atrophy in the transplanted kidney: a retrospective single-center cohort study.

Egeland EJ, Reisaeter AV, Robertsen I, Midtvedt K, Strøm EH, Holdaas H, Hartmann A, Åsberg A.

Transpl Int. 2019 Mar;32(3):257-269. doi: 10.1111/tri.13356. Epub 2018 Oct 15.

PMID:
30252957
8.

Pulse Pressure: A Risk Factor for Renal Transplant Failure or a Useful Therapeutic Target?

Tunbridge M, Holdaas H, Jardine AG.

Transplantation. 2019 Apr;103(4):662-663. doi: 10.1097/TP.0000000000002441. No abstract available.

PMID:
30188414
9.

Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score.

Ussif A, Pihlstrøm H, Pasch A, Holdaas H, Hartmann A, Smerud K, Åsberg A.

BMC Nephrol. 2018 Aug 22;19(1):212. doi: 10.1186/s12882-018-1000-8.

10.

Mid- and Long-Term Health Risks in Living Kidney Donors.

Mjoen G, Holdaas H.

Ann Intern Med. 2018 Aug 21;169(4):265. doi: 10.7326/L18-0340. No abstract available.

PMID:
30128523
11.

Lupus nephritis: low urinary DNase I levels reflect loss of renal DNase I and may be utilized as a biomarker of disease progression.

Pedersen HL, Horvei KD, Thiyagarajan D, Norby GE, Seredkina N, Moroni G, Eilertsen GØ, Holdaas H, Strøm EH, Bakland G, Meroni PL, Rekvig OP.

J Pathol Clin Res. 2018 Jul;4(3):193-203. doi: 10.1002/cjp2.99. Epub 2018 Apr 6.

12.

Immunosuppression Adherence in Stable Kidney Transplant Patients Converted From Immediate- to Prolonged-Release Tacrolimus in Clinical Practice: A Norwegian Study.

Abedini S, Gøransson L, Cockburn E, Kilany S, Holdaas H.

Transplant Direct. 2018 Feb 2;4(2):e338. doi: 10.1097/TXD.0000000000000755. eCollection 2018 Feb.

13.

Kidney allograft subclinical rejection modulates systemic inflammation measured by C-reactive protein at 1 year after transplantation.

García-Carro C, Dörje C, Åsberg A, Midtvedt K, Scott H, Reinholt FP, Holdaas H, Reisaeter AV, Seron D.

Clin Transplant. 2018 Mar;32(3):e13196. doi: 10.1111/ctr.13196. Epub 2018 Jan 30.

PMID:
29380890
14.

Long-term Change in the Risk of Skin Cancer After Organ Transplantation: A Population-Based Nationwide Cohort Study.

Rizvi SMH, Aagnes B, Holdaas H, Gude E, Boberg KM, Bjørtuft Ø, Helsing P, Leivestad T, Møller B, Gjersvik P.

JAMA Dermatol. 2017 Dec 1;153(12):1270-1277. doi: 10.1001/jamadermatol.2017.2984.

15.

Tacrolimus and mycophenolate regimen and subclinical tubulo-interstitial inflammation in low immunological risk renal transplants.

Torres IB, Reisaeter AV, Moreso F, Âsberg A, Vidal M, Garcia-Carro C, Midtvedt K, Reinholt FP, Scott H, Castellà E, Salcedo M, Dörje C, Sellarés J, Azancot MA, Perello M, Holdaas H, Serón D.

Transpl Int. 2017 Nov;30(11):1119-1131. doi: 10.1111/tri.13002. Epub 2017 Jul 27.

16.

Costimulation Blockade: America First, Canada Second … What About Norway?

Midtvedt K, Holdaas H, Bergan S, Åsberg A.

Am J Transplant. 2017 Aug;17(8):2230. doi: 10.1111/ajt.14351. Epub 2017 Jun 13. No abstract available.

17.

High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation.

Egeland EJ, Robertsen I, Hermann M, Midtvedt K, Størset E, Gustavsen MT, Reisæter AV, Klaasen R, Bergan S, Holdaas H, Hartmann A, Åsberg A.

Transplantation. 2017 Aug;101(8):e273-e279. doi: 10.1097/TP.0000000000001796.

PMID:
28452920
18.

Long term risk of mortality after living kidney donation.

Mjøen G, Holdaas H.

BMJ. 2017 Apr 25;357:j1770. doi: 10.1136/bmj.j1770. No abstract available.

PMID:
28442509
19.

Early introduction of oral paricalcitol in renal transplant recipients. An open-label randomized study.

Pihlstrøm HK, Gatti F, Hammarström C, Eide IA, Kasprzycka M, Wang J, Haraldsen G, Svensson MHS, Midtvedt K, Mjøen G, Dahle DO, Hartmann A, Holdaas H.

Transpl Int. 2017 Aug;30(8):827-840. doi: 10.1111/tri.12973. Epub 2017 Jun 2.

20.

Belatacept: Where the BENEFITS Outweigh the Risk.

Holdaas H, Mjøen G, Jardine AG.

Am J Kidney Dis. 2017 May;69(5):561-563. doi: 10.1053/j.ajkd.2017.02.007. No abstract available.

PMID:
28434523
21.

Regarding "Obesity increases the risk of end-stage renal disease among living kidney donors".

Mjøen G, Holdaas H.

Kidney Int. 2017 May;91(5):1256. doi: 10.1016/j.kint.2017.01.034. No abstract available.

PMID:
28407879
22.

Cardiovascular Parameters to 2 years After Kidney Transplantation Following Early Switch to Everolimus Without Calcineurin Inhibitor Therapy: An Analysis of the Randomized ELEVATE Study.

Holdaas H, de Fijter JW, Cruzado JM, Massari P, Nashan B, Kanellis J, Witzke O, Gutierrez-Dalmau A, Turkmen A, Wang Z, Lopez P, Bernhardt P, Kochuparampil J, van der Giet M, Murbraech K; ELEVATE Study Group.

Transplantation. 2017 Oct;101(10):2612-2620. doi: 10.1097/TP.0000000000001739.

PMID:
28333860
23.

Association Between Pretransplant Cancer and Survival in Kidney Transplant Recipients.

Dahle DO, Grotmol T, Leivestad T, Hartmann A, Midtvedt K, Reisæter AV, Mjøen G, Pihlstrøm HK, Næss H, Holdaas H.

Transplantation. 2017 Oct;101(10):2599-2605. doi: 10.1097/TP.0000000000001659.

PMID:
28207636
24.

Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.

Mafham MM, Staplin N, Emberson J, Haynes R, Herrington W, Reith C, Wanner C, Walker R, Cass A, Levin A, Fellström B, Jiang L, Holdaas H, Kasiske B, Wheeler DC, Landray MJ, Baigent C; SHARP Collaborative Group.

Nephrol Dial Transplant. 2018 Feb 1;33(2):257-264. doi: 10.1093/ndt/gfw396.

25.

Should patients older than 65 years be offered a second kidney transplant?

Heldal K, Hartmann A, Lønning K, Leivestad T, Reisæter AV, Line PD, Holdaas H, Midtvedt K.

BMC Nephrol. 2017 Jan 11;18(1):13. doi: 10.1186/s12882-016-0426-0.

26.

Outcome in biopsy-proven Lupus nephritis: Evaluation of biopsies from the Norwegian Kidney Biopsy Registry.

Norby GE, Mjøen G, Bjørneklett R, Vikse BE, Holdaas H, Svarstad E, Aasarød K.

Lupus. 2017 Jul;26(8):881-885. doi: 10.1177/0961203316686700. Epub 2017 Jan 6.

PMID:
28059018
27.

Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial.

de Fijter JW, Holdaas H, Øyen O, Sanders JS, Sundar S, Bemelman FJ, Sommerer C, Pascual J, Avihingsanon Y, Pongskul C, Oppenheimer F, Toselli L, Russ G, Wang Z, Lopez P, Kochuparampil J, Cruzado JM, van der Giet M; ELEVATE Study Group.

Am J Transplant. 2017 Jul;17(7):1853-1867. doi: 10.1111/ajt.14186. Epub 2017 Feb 14.

28.

Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update.

Holdaas H, De Simone P, Zuckermann A.

J Transplant. 2016;2016:4369574. Epub 2016 Oct 11. Review.

29.

Predictors of atherosclerotic events in patients on haemodialysis: post hoc analyses from the AURORA study.

Solbu MD, Mjøen G, Mark PB, Holdaas H, Fellström B, Schmieder RE, Zannad F, Herrington WG, Jardine AG.

Nephrol Dial Transplant. 2018 Jan 1;33(1):102-112. doi: 10.1093/ndt/gfw360.

PMID:
27798199
30.

Oxidized LDL, statin use, morbidity, and mortality in patients receiving maintenance hemodialysis.

Wagner S, Apetrii M, Massy ZA, Kleber ME, Delgado GE, Scharnagel H, März W, Metzger M, Rossignol P, Jardine A, Holdaas H, Fellström B, Schmieder R, Stengel B, Zannad F; on behalf AURORA study group and F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) network.

Free Radic Res. 2017 Jan;51(1):14-23. doi: 10.1080/10715762.2016.1241878. Epub 2017 Jan 25.

PMID:
27667446
31.

Single Nucleotide Polymorphisms and Long-Term Clinical Outcome in Renal Transplant Patients: A Validation Study.

Pihlstrøm HK, Mjøen G, Mucha S, Haraldsen G, Franke A, Jardine A, Fellström B, Holdaas H, Melum E.

Am J Transplant. 2017 Feb;17(2):528-533. doi: 10.1111/ajt.13995. Epub 2016 Sep 19.

32.

Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials.

Cholesterol Treatment Trialists' (CTT) Collaboration, Herrington WG, Emberson J, Mihaylova B, Blackwell L, Reith C, Solbu MD, Mark PB, Fellström B, Jardine AG, Wanner C, Holdaas H, Fulcher J, Haynes R, Landray MJ, Keech A, Simes J, Collins R, Baigent C.

Lancet Diabetes Endocrinol. 2016 Oct;4(10):829-39. doi: 10.1016/S2213-8587(16)30156-5. Epub 2016 Jul 29.

33.

Cardiac Assessment of Patients With Type 1 Diabetes Median 10 Years After Successful Simultaneous Pancreas and Kidney Transplantation Compared With Living Donor Kidney Transplantation.

Lindahl JP, Massey RJ, Hartmann A, Aakhus S, Endresen K, Günther A, Midtvedt K, Holdaas H, Leivestad T, Horneland R, Øyen O, Jenssen T.

Transplantation. 2017 Jun;101(6):1261-1267. doi: 10.1097/TP.0000000000001274.

PMID:
27467687
34.

Kidney-Failure Risk Projection for the Living Kidney-Donor Candidate.

Mjøen G, Holdaas H.

N Engl J Med. 2016 May 26;374(21):2094. doi: 10.1056/NEJMc1603007. No abstract available.

PMID:
27223156
35.

Inflammation in Early Kidney Allograft Surveillance Biopsies With and Without Associated Tubulointerstitial Chronic Damage as a Predictor of Fibrosis Progression and Development of De Novo Donor Specific Antibodies.

García-Carro C, Dörje C, Åsberg A, Midtvedt K, Scott H, Reinholt FP, Holdaas H, Seron D, Reisæter AV.

Transplantation. 2017 Jun;101(6):1410-1415. doi: 10.1097/TP.0000000000001216.

PMID:
27163535
36.

Total inflammation in early protocol kidney graft biopsies does not predict progression of fibrosis at one year post-transplant.

Dörje C, Reisaeter AV, Dahle DO, Mjøen G, Midtvedt K, Holdaas H, Flaa-Johnsen L, Syversveen T, Hartmann A, Jenssen T, Scott H, Reinholt FP.

Clin Transplant. 2016 Jul;30(7):802-9. doi: 10.1111/ctr.12753. Epub 2016 May 18.

PMID:
27101801
37.

Low-target tacrolimus in de novo standard risk renal transplant recipients: A single-centre experience.

Størset E, Åsberg A, Hartmann A, Reisaeter AV, Holdaas H, Skauby M, Bergan S, Midtvedt K.

Nephrology (Carlton). 2016 Oct;21(10):821-7. doi: 10.1111/nep.12738.

PMID:
26854648
38.

Overall and cardiovascular mortality in Norwegian kidney donors compared to the background population.

Mjøen G, Reisaeter A, Hallan S, Line PD, Hartmann A, Midtvedt K, Foss A, Dahle DO, Holdaas H.

Nephrol Dial Transplant. 2016 Jan;31(1):170. doi: 10.1093/ndt/gfv397. No abstract available.

PMID:
26740671
39.

Long-term cardiovascular outcomes in type 1 diabetic patients after simultaneous pancreas and kidney transplantation compared with living donor kidney transplantation.

Lindahl JP, Hartmann A, Aakhus S, Endresen K, Midtvedt K, Holdaas H, Leivestad T, Horneland R, Øyen O, Jenssen T.

Diabetologia. 2016 Apr;59(4):844-52. doi: 10.1007/s00125-015-3853-8. Epub 2015 Dec 28.

PMID:
26713324
40.

Regarding long-term outcome after kidney donation.

Mjøen G, Holdaas H.

Transpl Int. 2016 Mar;29(3):381. doi: 10.1111/tri.12717. Epub 2016 Jan 5. No abstract available.

41.

Serum Calcification Propensity Is a Strong and Independent Determinant of Cardiac and All-Cause Mortality in Kidney Transplant Recipients.

Dahle DO, Åsberg A, Hartmann A, Holdaas H, Bachtler M, Jenssen TG, Dionisi M, Pasch A.

Am J Transplant. 2016 Jan;16(1):204-12. doi: 10.1111/ajt.13443. Epub 2015 Sep 16.

42.

Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients--a three-yr serial echocardiographic substudy of the randomized controlled CENTRAL trial.

Murbraech K, Massey R, Undset LH, Midtvedt K, Holdaas H, Aakhus S.

Clin Transplant. 2015 Aug;29(8):678-84. doi: 10.1111/ctr.12565. Epub 2015 Jun 17.

PMID:
25982053
43.

Aortic Stiffness in a Mortality Risk Calculator for Kidney Transplant Recipients.

Dahle DO, Eide IA, Åsberg A, Leivestad T, Holdaas H, Jenssen TG, Fagerland MW, Pihlstrøm H, Mjøen G, Hartmann A.

Transplantation. 2015 Aug;99(8):1730-7. doi: 10.1097/TP.0000000000000660.

PMID:
25757216
44.

The authors reply:.

Mjøen G, Holdaas H.

Kidney Int. 2015 Mar;87(3):660. doi: 10.1038/ki.2014.400. No abstract available.

PMID:
25723634
45.

Homoarginine and Clinical Outcomes in Renal Transplant Recipients: Results From the Assessment of Lescol in Renal Transplantation Study.

Drechsler C, Pihlstrøm H, Meinitzer A, Pilz S, Tomaschitz A, Abedini S, Fellstrom B, Jardine AG, Wanner C, März W, Holdaas H.

Transplantation. 2015 Jul;99(7):1470-6. doi: 10.1097/TP.0000000000000568.

PMID:
25675199
46.

One-year protocol biopsies from ABO-incompatible renal allografts compared with a matched cohort of ABO-compatible allografts.

Dörje C, Mjøen G, Strøm EH, Holdaas H, Jenssen T, Øyen O, Akkök ÇA, Cvancarova M, Midtvedt K, Reisaeter AV.

Clin Transplant. 2015 Mar;29(3):268-76. doi: 10.1111/ctr.12515. Epub 2015 Feb 6.

47.

Increased risk of all-cause mortality and renal graft loss in stable renal transplant recipients with hyperparathyroidism.

Pihlstrøm H, Dahle DO, Mjøen G, Pilz S, März W, Abedini S, Holme I, Fellström B, Jardine AG, Holdaas H.

Transplantation. 2015 Feb;99(2):351-9. doi: 10.1097/TP.0000000000000583.

PMID:
25594550
48.

Selecting appropriate controls for kidney donors.

Mjøen G, Holdaas H.

Am J Transplant. 2015 Jan;15(1):286. doi: 10.1111/ajt.13016. Epub 2014 Oct 31. No abstract available.

49.

Long-term risks of kidney donation: age known.

Holdaas H, Mjoen G.

Am J Transplant. 2014 Nov;14(11):2671-2. doi: 10.1111/ajt.12971. Epub 2014 Oct 7. No abstract available.

50.

mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern?

Holdaas H, Potena L, Saliba F.

Transplant Rev (Orlando). 2015 Apr;29(2):93-102. doi: 10.1016/j.trre.2014.08.003. Epub 2014 Aug 27. Review.

PMID:
25227328

Supplemental Content

Loading ...
Support Center